Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Do not use during the 1st and 2nd third of pregnancy.
Fleas serve as intermediate hosts for one common type of tapeworm - Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.
Special precautions for use in animals
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
To minimise the risk of re-infestation and new infestation, excreta should be collected and properly disposed of for 24 hours following treatment.
The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
In very rare cases mild and transient digestive tract disorders such as vomiting and/or diarrhoea may occur. In individual cases these signs can be accompanied by nonspecific signs such as lethargy, anorexia or hyperactivity.
The frequency of adverse reactions is defined using the following convention:
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
No signs of adverse reactions were observed in safety studies in dogs and pups following administration of 10 times the recommended dose of the product.
Since it contains praziquantel, the product is effective against Echinococcus spp. which do not occur in all EU member states but are becoming more common in some. Echinococcosis represents a hazard for humans. As echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
In the interests of good hygiene, persons administering the product directly to a dog or by adding it to the dog’s food should wash their hands afterwards.
Use during pregnancy or lactation
Teratogenic effects attributed to high doses of febantel administered during early pregnancy have been reported in rats, sheep and dogs.
The safety of the product has not been investigated during the 1st and 2nd third of pregnancy. Do not use in pregnant dogs during the 1st and 2nd third of pregnancy.
A single treatment during the last third of pregnancy or during lactation has been demonstrated safe.
The anthelmintic effects of this product and piperazine containing products may be antagonised when the two drugs are used together. Concurrent use with other cholinergic compounds can lead to toxicity.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.